Loading stock data…
ROCHE PS (ROP.SW)
CHF 358.70-5.30 (-1.46%)
Market ClosedLast close Aug 28
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Roche Holding AG in the Healthcare sector is trading at $358.70 with a market capitalization of $285.8B. Wall Street consensus targets $370.31 (18 analysts), implying a +3.2% move over the next 12 months. The stock is currently near its 52-week high of $375.80, remaining 9.2% above its 200-day moving average. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Annual Financials
| Metric (CHF) · Annual | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total Revenue | CHF 65.81B↑ | CHF 60.44B↓ | CHF 62.40B↓ | CHF 63.36B |
| Gross Profit | CHF 46.08B↑ | CHF 44.08B↓ | CHF 46.11B↓ | CHF 46.71B |
| Operating Income | CHF 17.48B↑ | CHF 15.39B↑ | CHF 13.42B↓ | CHF 18.48B |
| Net Income | CHF 12.42B↑ | CHF 11.50B↑ | CHF 8.28B↓ | CHF 12.88B |
Peer Comparison
JNJUNHPFE
Fundamentals
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tum...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
CHF 285.80B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.41
Beta
Defensive asset. Lower volatility than the S&P 500.
0.35
Div Yield
Strong income play. Yield provides a meaningful total return floor.
269.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
38.11%
Volume
Today's trading volume
803,233
Recent News
Roche Holding (SWX:ROP) Secures FDA Clearance For Alzheimer’s Blood Test
Roche Holding (SWX:ROP) received FDA approval for its Elecsys pTau217 blood test for Alzheimer's disease in the U.S. The Elecsys pTau217 test is designed to identify amyloid pathology using a blood sample, widening access to dementia diagnostics across U.S. labs. The FDA also cleared expanded use of Roche's PATHWAY HER2 and VENTANA HER2 Dual ISH tests in metastatic gastroesophageal cancers. These approvals broaden options for HER2 testing in cancer care and support more tailored treatment...
BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna’s Big Win
BioNTech says it’s ending a Phase 2 trial for its investigational personalized mRNA cancer vaccine. It was being tested to treat colorectal cancer.
BioNTech Kills a Cancer Trial Roche Helped Build
One colorectal failure does not destroy the platform, but it exposes how brutally tumor biology can defeat elegant technology.
BNTX Stock On Track For Worst Day Since March After Cancer Vaccine Trial Halt — BMO Capital Terms It ‘Clear Setback’
BioNTech said on Friday that it and its partner, Genentech, a Roche unit, are ending the mid-stage study of autogene cevumeran, used alone after surgery, in certain high-risk stage II or III colorectal cancer patients.
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.